Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/immune-stimulating-conjugates-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Immune Stimulating ConjugatesImmune Stimulating Conjugates: Patent Filing Patterns and Where the Field Is Still Open
- Top 5 assignees hold 53.8% of all 411 records, and the top 10 combined reach 72.7% — concentration builds fast past the leader.
- Filings peaked at 55 in 2021 and fell to 15 by 2024, a -73% swing over three years, though 2025-26 counts are still filling in.
- A61K coverage sits at 92.0% of records, while steroid-linked (C07J) and biocide-adjacent (A01N) classes stay under 3% each — narrow but largely unclaimed.
411
Published Records
54%
Top-5 Share of All Records
-73%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (55 records) with 2024 (15) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 411 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the immune stimulating conjugate patent record shows
Immune stimulating conjugates pair a targeting or antibody component with an innate-immune trigger — most often a TLR agonist — so that adjuvant activity is delivered where it is needed rather than systemically. The claim language in this dataset clusters around controlling where and how that activation happens: tumor localized release, payload potency tuning and avoiding dose limiting toxicity recur as the mechanisms assignees actually try to own, rather than the conjugate chemistry alone.
The 411 records in scope span 2015 through the 2026 cut-off, with United States, WIPO/PCT and European filings carrying the bulk of the receiving-office activity. Filing density is heaviest in medicinal preparations and therapeutic-activity classes, which is expected for a field built on antibody and small-molecule combination therapy, but it leaves several adjacent technical branches comparatively thin.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology composition
Two views of the same 411-record set: how filing activity moved year over year, and how those records distribute across IPC subclasses. Both are read against the same denominator so the shares are directly comparable.
Filing activity, 2017-2026
Filings rose to a peak of 55 in 2021 and had fallen to 15 by 2024 — a -73% move across that span. 2025 and 2026 figures will continue to rise as publication catches up with filing, so treat the tail of the trend as incomplete rather than as evidence of a slowdown.
IPC subclass distribution
A61K (medicinal preparations) appears in 92.0% of the 411 records, with A61P (therapeutic activity) and C07K (peptides & proteins) each present in over a third. Because records can carry multiple IPC codes, these percentages sum past 100% — the useful read is relative density, not a partition of the corpus.
Shares are the percentage of the 411 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Immune Stimulating Conjugates with Eureka
This page is one run against one query. Ask Eureka your own question about immune stimulating conjugates and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative and most-cited filings
Representative filing
EP2739309A1 — TLR agonist and antigen-specific antibody composition for vaccine use
GLAXOSMITHKLINE BIOLOGICALS S.A.
The invention provides a TLR agonist and an antibody which binds to an antigen, such as a beta-amyloid antigen, for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before it, or after it. The compositions and methods described are aimed at prevention or treatment of Alzheimer's disease.Filed by Glaxosmithkline Biologicals, dated 2014-06-11 — included here as representative of the timing-of-delivery claim style common across this dataset.
View full filingMost-cited records in this dataset
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20090074711A1 | Human therapies using chimeric agonistic Anti-human CD40 antibody | 102 |
| 2 | WO2012019041A2 | Regulatory b cells and their uses | 68 |
| 3 | US20070190063A1 | Antibody-mediated enhancement of immune response | 68 |
| 4 | WO2016123573A1 | Peritumoral and intratumoral materials for cancer therapy | 62 |
| 5 | US20130295110A1 | Prostate-associated antigens and vaccine-based immunotherapy regimens | 59 |
| 6 | WO2007022520A2 | Antibody-mediated enhancement of immune response | 40 |
| 7 | US20070190029A1 | Listeria-induced immunorecruitment and activation, and methods of use thereof | 37 |
| 8 | WO2015063647A1 | Vectors for expression of prostate-associated antigens | 34 |
| 9 | WO2013164754A2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | 29 |
| 10 | WO2020227159A2 | Methods of modulating immune activity | 25 |
Citation counts are measured inside this searched corpus and skew toward older filings that have simply had more time to accumulate citations — read them as a signal of influence on the field, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the concentration and trend numbers mean
Three figures from this dataset matter more than the rest for anyone deciding where to file or where to look for freedom to operate.
Concentration
53.8%
of 411 records held by top 5
Ownership concentrates fast at the top
The five leading assignees account for 221 of the 411 records in scope, and the top 10 extend that to 72.7%. That leaves a long tail of single- or few-filing entrants below rank ten, which is where most new entrants in this space actually sit today.
Ranking covers 91 companies, the full set the data endpoint returns.
Momentum
-73%
2021 peak to 2024
Filing activity has cooled from its 2021 peak
Annual filings hit 55 in 2021, the high point of the dataset, and had dropped to 15 by 2024. Because publication lags filing by roughly 18 months, 2025 and 2026 counts are not yet complete and should not be read as continuing the decline.
2024 is the most recent year treated as complete.
Technology mix
92.0%
of records touch A61K
Claim density sits almost entirely in medicinal preparations
Nearly all records carry an A61K classification, with A61P and C07K present in well over a third of filings. Steroid-linked (C07J) and biocide-adjacent (A01N) classifications each appear in under 3% of records, a much sparser footprint for the same underlying mechanism.
Class shares sum past 100% because records carry multiple IPC codes.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to immune stimulating conjugates, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the gaps sit
The ranked leaders span large pharmaceutical companies, specialist biotech developers and academic medical centres, several of which co-file with research hospital partners rather than filing solely in their own name.
Leader
120
records
A single assignee holds a clear lead
The top-ranked assignee holds 120 records, well ahead of fifth place at 17 and tenth place at 13 — the drop-off after the leader is steep rather than gradual.
Counted across the full 411-record set.
Co-filing
17
strongest pair
Academic-industry pairs recur in co-assignee data
Ten co-assignee pairs appear in the dataset, the strongest linking an academic health sciences center with a pharmaceutical partner at 17 shared records — a pattern consistent with translational research moving from university labs into applied conjugate programs.
Ten total co-assignee pairs identified.
Momentum
0
latest-year filings, leading assignees
Even top assignees show no latest-year activity yet
Several of the most active historical filers, including the top-ranked assignee, show zero recorded filings in the latest year, consistent with the publication lag rather than a stop in R&D activity.
Read alongside the 2025-26 publication lag noted above.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Pfizer Inc | 0 | — |
| Flagship Pioneering Innovations V Inc | 0 | — |
| ALX Oncology Inc | 0 | -100% |
| Adjuvance Technologies Inc | 0 | — |
| Juno Therapeutics Inc | 0 | — |
| Oregon Health & Science University | 0 | -100% |
| PDX Pharmaceuticals Inc | 0 | -100% |
| Dana-Farber Cancer Institute Inc | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to a field with a dominant early filer, a cooling-but-incomplete recent trend, and technical branches that remain thin relative to the core. The next step depends on whether you are filing, licensing, or clearing a product.
Check freedom to operate against the leader's portfolio
With one assignee holding 120 of 411 records, any conjugate program using antibody-TLR agonist pairing should map its claims against that portfolio specifically, not just the field average.
Explore assignee portfolios in EurekaInvestigate the under-claimed branches before drafting
Steroid-linked and sugar/nucleic-acid linker chemistries show markedly lower filing density than the A61K core — worth a focused search before committing claim language there.
Run a white space search in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on immune stimulating conjugate patents
This dataset is built from filings claiming a targeting or antibody component conjugated or co-administered with an innate-immune trigger, most commonly a TLR agonist, together with claims addressing systemic exposure control, tumor-localized release, or dose-limiting toxicity. It spans 411 published records from 2015 through the 2026 data cut-off. The search string combines conjugate and adjuvant terminology with functional claim language rather than a single chemical class, so the corpus includes both antibody-drug-conjugate-style filings and vaccine adjuvant compositions.
One assignee leads the ranked field with 120 of the 411 records, well ahead of fifth place at 17 and tenth place at 13. The top 5 assignees combined hold 53.8% of all records, and the top 10 reach 72.7%, so ownership concentrates heavily near the top even though the ranking itself covers 91 companies. Below the top ten, filing activity spreads thinly across a long tail of single- and few-record entrants.
Filings peaked at 55 in 2021 and had fallen to 15 by 2024, a -73% change over that span, which reads as a genuine cooling in the years that are fully published. However, patent publication typically lags filing by around 18 months, so 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirming a continued decline. 2024 is the most recent year that can be treated as a complete data point.
The technology composition data shows A61K present in 92.0% of records and A61P and C07K each above a third, but classes like C07J (steroids) and A01N (biocides/agrochemicals) sit under 3% each. That gap suggests steroid-conjugated TLR agonist payloads and certain linker chemistries carry much lower claim density than the core antibody-adjuvant combination space, making them worth a dedicated search before drafting new claims there.
EP2739309A1 claims a TLR agonist and an antigen-specific antibody used together, including specific delivery timing windows relative to the antibody, for stimulating an immune response — originally directed at Alzheimer's disease indications via a beta-amyloid antigen. Anyone filing conjugate or co-administration claims that turn on the timing of TLR agonist delivery relative to an antibody should check overlap with this filing and its family members. Because it is one of the more heavily cited records in this dataset, it is also a useful reference point for how examiners have treated timing-based claim language in this space.
Answers are grounded in the same dataset. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Immune Stimulating Conjugates in depth with Eureka
Go past this page: query the whole immune stimulating conjugates corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.